LUCRIN

This brand name is authorized in Australia, Israel, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, Turkey.

Active ingredients

The drug LUCRIN contains one active pharmaceutical ingredient (API):

1	Leuprorelin UNII 37JNS02E7V - LEUPROLIDE ACETATE
	Leuprorelin is inactive when given orally due to poor membrane permeability and an almost complete inactivation by intestinal proteolytic enzymes. Leuprorelin has potent LHRH agonist properties when given during short-term and intermittent therapy, however, when administered in a continuous, nonpulsatile manner, LHRH analogs induce inhibition of gonadotropin secretion and suppression of testicular steroidogenesis.
	Read more about Leuprorelin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUCRIN Depot Solution for injection	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AE02	Leuprorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11943N, 11944P, 11960L, 8875D, 8876E, 8877F
IL	מִשְׂרַד הַבְּרִיאוּת	3483, 4101
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	443M89, 468M90
NL	Z-Index G-Standaard	13295292
NL	Z-Index G-Standaard, PRK	64815, 76589, 76597, 89214
NZ	Medicines and Medical Devices Safety Authority	12227, 12246
PL	Rejestru Produktów Leczniczych	100039890, 100247418
SG	Health Sciences Authority	05265P, 08862P, 10742P, 14004P
TR	İlaç ve Tıbbi Cihaz Kurumu	8680656080117, 8680656080124, 8680656080131, 8680656080148, 8680656080155
ZA	Health Products Regulatory Authority	S/21.10/51